Anavex Life Sciences Corp. (AVXL) Stock Price Down 6.2%
Anavex Life Sciences Corp. (NASDAQ:AVXL) fell 6.2% on Monday . The company traded as low as $3.39 and last traded at $3.47, with a volume of 1,061,401 shares trading hands. The stock had previously closed at $3.70.
A number of brokerages have weighed in on AVXL. FBR & Co reiterated an “outperform” rating and set a $10.00 target price on shares of Anavex Life Sciences Corp. in a research note on Monday. Maxim Group set a $15.00 target price on shares of Anavex Life Sciences Corp. and gave the company a “buy” rating in a research note on Wednesday, July 27th. Finally, Zacks Investment Research lowered shares of Anavex Life Sciences Corp. from a “buy” rating to a “hold” rating in a research note on Tuesday, July 12th.
The company’s market capitalization is $118.56 million. The company has a 50 day moving average of $5.35 and a 200-day moving average of $4.84.
Anavex Life Sciences Corp. (NASDAQ:AVXL) last issued its quarterly earnings data on Thursday, August 11th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.03. Equities research analysts anticipate that Anavex Life Sciences Corp. will post ($0.34) earnings per share for the current fiscal year.
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.